Mississippi pharmacy board says a certificate of analysis alone does not make a peptide compoundable

Summary. The Mississippi Board of Pharmacy's October 2026 newsletter publishes a question-and-answer follow-up to the joint statement on research-grade peptides that the state's boards of pharmacy, nursing and medical licensure issued on 19 August 2026, and one answer addresses a common question about certificates of analysis directly: "A certificate of analysis alone does not satisfy the concerns of the statement." It appears while FDA's federal notice "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) is still under White House review, with its text, covered substances and conditions unpublished.

Research context (RUO). According to the board, a compounding pharmacy using a peptide bulk substance needs more than a COA: the material must be sourced from an FDA-registered establishment, must meet the federal compounding exemptions, and must have an applicable USP or NF monograph, be a component of an FDA-approved drug, appear on the applicable FDA bulks list or be actively listed under FDA's interim Category 1 policy. It also must not be essentially a copy of a commercially available drug. The Q&A adds that a "not for human use" disclaimer does not remove the potential for enforcement action against licensees, and that giving use information directly or through an unaffiliated website counts as recommending. The August statement itself says licensed providers in Mississippi may not compound, administer, dispense, prescribe or recommend non-FDA-approved or research-grade peptides, and must buy prescription products and ingredients from entities permitted by the board. These are state rules for licensed professionals in one state. The federal picture is unchanged: FDA's own reviewers recommended against all seven peptides reviewed in July, and the Pharmacy Compounding Advisory Committee then voted to recommend six of the seven. That is a recommendation, and no FDA notice listing six peptides exists. Holland & Knight notes that adding a substance to the 503A bulks list requires a proposed rule, public comment and a final rule. On 28 October the reginfo.gov meeting log for RIN 0910-ZD94 listed four outside-party meetings, the latest two on 27 October. In documentation terms, the board's answer separates two questions. A lot-level COA describes what one batch is: its identity, purity and impurity profile, with the lot number, test methods, laboratory and date. Whether a substance may legally be compounded is a separate regulatory status that no COA can establish.

Related: FDA Peptide Compounding Policy Tracker 2026, a sourced status page for the interim notice, the July advisory votes and the 503A bulks list.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.